Press release

Sandoz Inc. 506 Carnegie Center Drive, Suite 400 Princeton, NJ 08540 Phone +1 609 627 8500 Fax +1 609 627 8682
Sandoz launches authorized versions of Cozaar® and Hyzaar® tablets
Princeton, NJ, April 7, 2010 —Sandoz Inc. announced today the introduction in the US of losartan
potassium and losartan potassium-hydrochlorothiazide (HCTZ) tablets, authorized generic equivalents of
Merck's Cozaar® and Hyzaar®. Losartan potassium and losartan potassium-HCTZ tablets are intended
for the treatment of hypertension.
Sandoz will market losartan potassium in 25mg, 50mg and 100mg strength tablets, and losartan
potassium-HCTZ in 50/12.5mg, 100/12.5mg and 100/25mg strength tablets, the same dosage strengths
and formulations as Cozaar® and Hyzaar®, respectively.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as
“wil ,” “risk,” or similar expressions, or by express or implied discussions regarding potential future
revenues from losartan potassium and losartan potassium HCTZ tablets. You should not place undue
reliance on these statements. Such forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future results, performance or achievements
expressed or implied by such statements. Management’s expectations regarding losartan potassium and
losartan potassium HCTZ tablets could be affected by, among other things, unexpected regulatory actions
or delays or government regulation generally; unexpected inabilities to obtain or maintain exclusivity
periods for our product; competition in general; the impact that the foregoing factors could have on the
values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the
US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary materially from those
anticipated, believed, estimated or expected. Novartis is providing the information in this press release as
of this date and does not undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
About Sandoz
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering
a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a
portfolio of about 1000 compounds and sells its products in more than 130 countries. Key product groups
include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines,
cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these
medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In
addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US) and EBEWE Pharma (Austria). In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion.
For further information
Sandoz US Communications:
Ted Deutsch
(609) 627-5287
Sandoz Global Communications:
Chris Lewis
+49 172 141 8749
Novartis Investor Relations (North America)
Richard Jarvis
(212) 830-2433
Cozaar® and Hyzaar® are registered trademarks of Merck.
Page 2 of 2

Source: http://www.sandoz.by/assets/media/shared/documents/press_releases/100408_Losartan_LosartanHCTZ.pdf